Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 30,348 | 23,421 | 59,153 | 46,439 |
| Research and development | 90,528 | 46,067 | 188,438 | 87,111 |
| Acquired in-process research and development | 16,435 | — | 742,737 | 5,000 |
| Selling, general and administrative | 81,469 | 63,286 | 177,799 | 120,992 |
| Total operating expenses | 218,780 | 132,774 | 1,168,127 | 259,542 |
| Loss from operations | (42,537) | (4,989) | (832,002) | (20,172) |
| Other income (expense): | ||||
| Interest income | 3,851 | 3,033 | 7,252 | 6,056 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s SG&A?
- Mirum Pharmaceuticals, Inc. (MIRM) reported SG&A of $81.47M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s SG&A increased by 28.7% year-over-year, from $63.29M to $81.47M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s SG&A has grown at a 44.3% compound annual growth rate (CAGR), from $59.22M to $257.03M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Mirum Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude